SQI Seeks to Raise $9M in Private Placement | GenomeWeb

NEW YORK (GenomeWeb News) – Microarray-based diagnostics firm SQI announced late on Thursday its intention to complete a non-brokered private placement of more than 5 million units to raise gross proceeds of up to C$9 million (US$9 million).

The Toronto-based firm said it plans to place up to 5,142,857 units for C$1.75 per unit. Each unit will consist of one common share and one common share purchase warrant, which will entitle its holder to purchase one common share for C$2.50 for a period of two years from the date of issuance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.